Chief scientist Shaw looks for unusual sources of return in MNKD and VRX.
MannKind Corporation (NASDAQ:MNKD) shares inched lower on Wednesday after rising to 52-week highs in the previous session. The reason?
Oren Livnat expects MannKind’s inhaled insulin’s new label will be a real game-changer.
Mannkind caught a price target boost from Maxim in the wake of a positive label revision for Afrezza.
Investors are racing to buy MannKind Corporation (NASDAQ:MNKD) shares following the news that the FDA has approved a labeling revision for the company’s diabetes …
